BioCentury

7:00 AM GMT, Mar 16, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/13 cls
Genmab (CSE:GEN) UBS Guillaume van Renterghem Upgrade Buy (from neutral) 0% DKK221.25
van Renterghem upgraded in anticipation of FDA acceptance and potential Priority Review of a BLA for Arzerra ofatumumab to treat chronic lymphocytic leukemia (CLL). He expects acceptance in the coming weeks and approval of the mAb against

Read the full 765 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.